A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial

Mease PJ;Smolen JS;Behrens F;Nash P;Leage SL;Li LN;Tahir H;Gooderham M;Krishnan E;Liu-Seifert H;Emery P;Pillai SG;Helliwell PS;Naftal L;Hidalgo RAP;Kerzberg EM;Savio VG;Lazaro A;Velasco BJ;Verzero NB;Asnal CA;Mysler EF;Berman A;Ariel FJ;Rischmueller M;Zochling JM;Bird PA;Hall S;Ostor A;Romas E;Stummvoll G;Machold K;Spellitz P;Hanusch U;Vanden Berghe M;Leon M;Vanhoof JLM;Van den Bosch FEJ;De Vlam KLF;Morin F;Bessette L;Haaland DA;Schlemmer AM;Kristensen LE;Jarvinen P;Peltomaa RL;Pirila L;Vuotila J;Lespessailles E;Goupille P;Combe B;Constantin A;Cormier G;Cozic C;Confavreux CB;Schulze-Koops H;Everding A;Kohm M;Wassenberg S;Nagy M;Bakos N;Melegh E;Drescher E;Duggal L;Joshi PN;Zoha SG;Naidu AR;Srivastava PP;Sharma VD;Nalawadae AB;Oak JL;Veeravalli SCM;Kadel JK;Daware MA;Marfatia YS;Agarwal S;Moscovici YB;Elkayam O;Molad Y;Reitblat T;Tishler M;Levy Y;Lidar M;Zisman D;Costanzo A;Amerio P;Meliconi R;Foti R;Perricone R;Rossini M;Gremese E;Montiel BEZ;Limon JMM;Cecena MAM;Ayala SAS;Guerrero MAA;Serrano JR;Novelo EAC;Cons-Molina FF;Griep EN;Kaszuba A;Weglowska JB;Bazela B;Rell-Bakalarska M;Miakisz M;Spargo CE;Van Duuren EM;Naidoo A;Matsiliza NC;Breedt J;Tarr GS;Potts J;Nayiager S;Ally MMTM;Garcia FJB;Varela AM;Rosas J;Burson JMS;Miguel JG;Lampa J;Rizk M;Cagnotto G;Larsson P;Fei G;Mueller-Mar R;Rubbert-Roth A;Nissen MJ;Iaremenko O;Trypilka SA;Rekalov D;Stanislavchuk M;Vasylets VV;Garmish O;Smiyan S;Walker D;Jadon D;Ralston S;Boyle S;Watson PA;Dale JE;Carty S;Douglas K;Edwards CJ;Hutchinson D;Barkham N

2020-01-01